refractory precursor T-lymphoblastic lymphoma/leukemia

Summary

refractory precursor T-lymphoblastic lymphoma/leukemia (MONDO:0004404) is a cancer and 1 clinical trial. A subtype of T lymphoblastic leukemia/lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	refractory precursor T-lymphoblastic lymphoma/leukemia
Mondo ID	MONDO:0004404
DOID	DOID:7936
NCIT	C8696
UMLS	C0854859
MedGen	167728
GARD	0023983
Is cancer (heuristic)	yes

Also known as: precursor T lymphoblastic lymphoma/leukemia refractory · refractory precursor T-lymphoblastic lymphoma/leukemia · refractory T lymphoblastic leukemia/lymphoma

Disease family

This is a subtype of T lymphoblastic leukemia/lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › precursor lymphoblastic lymphoma/leukemia › T lymphoblastic leukemia/lymphoma › refractory precursor T-lymphoblastic lymphoma/leukemia

Related subtypes (4): childhood precursor T-lymphoblastic lymphoma/leukemia, T-cell prolymphocytic leukemia, aggressive NK-cell leukemia, T-lymphoblastic lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04689659	PHASE2	COMPLETED	Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma